Revolutionising the treatment of eczema with novel peptide technology
Carocell Bio is more than just a name - it’s an evolution in skincare
We are at the forefront of a peptide-based, anti-inflammatory approach to heal and promote healthier skin and help treat skin-related conditions
Treatment of Eczema (Atopic Dermatitis)
Eczema (atopic dermatitis) is the most common skin disease, and is often a chronic condition
Current treatments carry significant safety risks
Our lead peptide, JEL3108, works in biopsies from patients with eczema
Our novel peptide technology will safely revolutionise the management of eczema
Prevention - stops eczema coming back
Our patented peptide can not only treat eczema – if its use is continued, it will be able to prevent the disease coming back
Giving you healthier, happier skin over the longer-term
Delay skin ageing
A significant component of skin ageing is related to inflammation
Our treatment, which is developed for topical application to the skin, has the potential to be used as an anti-ageing treatment
Carocell Bio would be more than happy to discuss any of these indications
Our Research and Data.
We have proprietary peptide-based anti-inflammation technology, with highly potent and highly selective therapeutic peptides that inhibit intracellular mitogen-activated protein kinase (MAPK, p38).
Our portfolio of novel molecules inhibit the inflammatory cascade, combining them with a nanoparticle delivery technology that can be applied to the skin.
Our Leadership Team
Carocell Bio’s leadership team has extensive global experience in drug development – from idea through to market
Dr Mike Davies MD, FRCS
CEO & Founder
John Nicholson, PhD
40 years life-science experience translating scientific discoveries to deliver global market impact.
NHS biochemist, Amersham international, J&J, Philips, Oxford and other University spin-outs, MediCity/ BioCity, multiple advisory and Board roles